翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03692 翰森制药

已收盘 10-12 16:08:17

31.560

+0.020

+0.06%

最高32.580	最低31.540	成交量507.79万
今开31.540	昨收31.540	日振幅3.30%
总市值1,914亿	流通市值1,914亿	总股本60.64亿
成交额1.61亿	换手率0.08%	流通股本60.64亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03692","market":"HK","secType":"STK","nameCN":"翰森制药","latestPrice":31.56,"timestamp":1791792497006,"preClose":31.54,"halted":0,"volume":5077865,"delay":0,"changeRate":0.0006341154090044253,"floatShares":6064000000,"shares":6064000000,"eps":1.090094170825878,"marketStatus":"已收盘","change":0.02,"latestTime":"10-12 16:08:17","open":31.54,"high":32.58,"low":31.54,"amount":161240262,"amplitude":0.032974,"askPrice":31.56,"askSize":14000,"bidPrice":31.54,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":1.298364281099915,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791855000000},"marketStatusCode":5,"adr":0,"listingDate":1560441600000,"exchange":"SEHK","adjPreClose":31.54,"dividendRate":0.015704,"openAndCloseTimeList":[[1791768600000,1791777600000],[1791781200000,1791792000000]],"volumeRatio":0.743393,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03692/wiki","defaultTab":"wiki","newsList":[{"id":"2674581741","title":"阿美替尼重启欧盟上市进程 申报获EMA迅速受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2674581741","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674581741?lang=zh_cn&edition=full","pubTime":"2026-10-11 19:44","pubTimestamp":1791719041,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1583","BK1191","03692","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674817685","title":"翰森制药：阿美替尼重新提交欧盟上市申请获EMA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2674817685","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674817685?lang=zh_cn&edition=full","pubTime":"2026-10-11 19:07","pubTimestamp":1791716840,"startTime":"0","endTime":"0","summary":"10月11日，翰森制药公告称，集团于2026年9月29日向欧洲药品管理局（EMA）重新递交创新药阿美替尼（海外商品名：Aumseqa?）在欧盟的上市许可申请，2026年10月7日获EMA确认受理并正式启动集中审批程序。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610113892084951.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610113892084951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1589","BK1583","03692","IPOS","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173950683","title":"翰森制药(03692)阿美替尼重新递交欧盟上市许可申请并获EMA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1173950683","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173950683?lang=zh_cn&edition=full","pubTime":"2026-10-11 18:35","pubTimestamp":1791714924,"startTime":"0","endTime":"0","summary":"翰森制药集团有限公司10月11日公告称，公司已于2026年9月29日向欧洲药品管理局重新递交创新药阿美替尼在欧盟的上市许可申请。EMA已于2026年10月7日确认受理该申请，并正式启动集中审批程序。1) 表皮生长因子受体外显子19缺失或外显子21置换突变的晚期非小细胞肺癌成人患者一线治疗；2) EGFR T790M突变阳性的晚期NSCLC成人患者治疗。本次重新递交及获受理为继2026年9月27日公告更新后，阿美替尼在欧盟上市进程的最新进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175482943","title":"异动解读｜翰森制药盘中下跌3.01%，大股东关联方减持叠加欧盟许可撤销余波","url":"https://stock-news.laohu8.com/highlight/detail?id=1175482943","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175482943?lang=zh_cn&edition=full","pubTime":"2026-10-08 13:39","pubTimestamp":1791437986,"startTime":"0","endTime":"0","summary":"10月8日，翰森制药盘中下跌3.01%，报32.9港元，成交额1.98亿港元。虽然减持规模有限，但大股东关联方同步动作引发市场关注。翰森制药集团有限公司主要从事药品研发、生产及销售，创新药产品覆盖抗肿瘤、抗感染、中枢神经系统疾病、代谢等治疗领域，主要于国内市场开展业务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"翰森制药下跌，大股东减持叠加欧盟许可撤销","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704094","title":"Cantrust (Far East) Limited减持瀚森制药(03692.HK)12.4万股 每股作价约33.96港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704094","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673704094?lang=zh_cn&edition=full","pubTime":"2026-10-05 19:13","pubTimestamp":1791198794,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1589","BK1191","BK1583","03692","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704015","title":"Cantrust (Far East) Limited减持瀚森制药(03692)12.4万股 每股作价约33.96港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704015","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673704015?lang=zh_cn&edition=full","pubTime":"2026-10-05 19:13","pubTimestamp":1791198794,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，10月2日，Cantrust (Far East) Limited减持瀚森制药(03692)12.4万股，每股作价33.9623港元，总金额约为421.13万港元。减持后最新持股数目约为9.2亿股，最新持股比例为15.16%。本交易涉及其他关联方：APEX MEDICAL COMPANY LTD.、JQC Holding Limited、JQC International Limited、岑均达。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1503727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","03692","BK1574","EWH","BK1583","BK1589","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131588974","title":"翰森制药：JQC International Limited减持，好仓比例降至15.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131588974","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131588974?lang=zh_cn&edition=full","pubTime":"2026-10-05 17:23","pubTimestamp":1791192232,"startTime":"0","endTime":"0","summary":"JQC International Limited于2026年10月2日在联交所场内以每股均价33.9623港元卖出翰森制药12.40万股，涉资约421.13万港元。属场内主动交易，即在二级市场直接买卖股份。JQC International Limited此次减持前持有翰森制药好仓9.20亿股，占比15.17%；减持后持股量为9.20亿股，好仓比例降至15.16%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134918398","title":"翰森制药：APEX MEDICAL COMPANY LTD.减持，好仓比例降至15.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1134918398","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134918398?lang=zh_cn&edition=full","pubTime":"2026-10-05 17:15","pubTimestamp":1791191730,"startTime":"0","endTime":"0","summary":"APEX MEDICAL COMPANY LTD.于2026年10月2日在联交所场内以每股均价33.9623港元卖出翰森制药12.40万股，涉资约421.13万港元，属场内主动交易，即在二级市场直接买卖股份。APEX MEDICAL COMPANY LTD.此次减持前持有翰森制药好仓9.20亿股，占比15.17%；减持后持股量为9.20亿股，好仓比例降至15.16%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161856260","title":"翰森制药：岑均达减持，好仓比例降至15.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1161856260","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161856260?lang=zh_cn&edition=full","pubTime":"2026-10-05 17:15","pubTimestamp":1791191730,"startTime":"0","endTime":"0","summary":"岑均达于2026年10月2日在联交所场内以每股均价33.9623港元卖出翰森制药股份12.40万股，涉资约421.13万港元，属场内主动交易，即在二级市场直接买卖股份。岑均达此次减持前持有翰森制药好仓9.20亿股，占比15.17%；减持后持股量为9.20亿股，好仓比例降至15.16%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173577608","title":"翰森制药：JQC Holding Limited减持，好仓比例降至15.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173577608","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173577608?lang=zh_cn&edition=full","pubTime":"2026-10-05 17:14","pubTimestamp":1791191675,"startTime":"0","endTime":"0","summary":"JQC Holding Limited于2026年10月2日在联交所场内以每股均价33.9623港元卖出翰森制药12.40万股，涉资约421.13万港元，属场内主动交易，即在二级市场直接买卖股份。JQC Holding Limited此次减持前持有翰森制药好仓9.20亿股，占比15.17%；减持后持股量为9.20亿股，好仓比例降至15.16%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189793243","title":"翰森制药9月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1189793243","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189793243?lang=zh_cn&edition=full","pubTime":"2026-10-02 16:40","pubTimestamp":1790930409,"startTime":"0","endTime":"0","summary":"翰森制药集团有限公司于2026年10月2日公布截至2026年9月30日的证券变动月报表。本期内，公司注册股本维持在200,000港元，股份数为20,000,000,000股，每股面值0.00001港元，与上月数额一致。公司披露，9月底已发行普通股股份总数为6,064,150,070股，无库藏股份，较上月保持不变，未发生新增发行、购回或注销股行为。公司表示目前已满足适用的最低公众持股量要求16.21%。截至报告期末，股本总数保持稳定。本份公告由翰森制药集团有限公司联席公司秘书郭颖女士签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150429954","title":"异动解读｜翰森制药盘中下跌3.97%，阿美替尼欧盟撤证余波未消叠加医药板块整体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1150429954","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150429954?lang=zh_cn&edition=full","pubTime":"2026-10-02 10:51","pubTimestamp":1790909473,"startTime":"0","endTime":"0","summary":"10月2日，翰森制药盘中下跌3.97%，报33.9港元，成交额3.59亿港元。消息面上，阿美替尼欧盟上市许可于9月25日因程序瑕疵被撤销，阿斯利康就翰森申报资料中引用奥希替尼数据保护期内临床结果提起诉讼，欧盟委员会在诉讼审结前即启动撤销程序。翰森制药表示该决定与药品质量、安全性及有效性无关，拟尽快基于原始数据重新递交上市申请。阿美替尼目前尚未在海外产生销售收入，英国批件仍然有效。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"翰森制药盘中走弱，阿美替尼欧盟撤证余波发酵","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112895544","title":"异动解读｜翰森制药盘中上涨3.16%，竞品B7-H3 ADC申请撤回叠加医药板块走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1112895544","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112895544?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:39","pubTimestamp":1790735943,"startTime":"0","endTime":"0","summary":"9月30日，翰森制药盘中上涨3.16%，报34.58港元，成交额1.24亿港元。小摩维持翰森制药\"增持\"评级，目标价50港元。此外，翰森制药核心ADC产品HS-20093的小细胞肺癌及骨肉瘤两项适应症上市申请均已获NMPA受理并纳入优先审评。今日制药板块整体走强，石药集团涨6.39%、恒瑞医药涨6.01%、中国生物制药涨3.96%，板块共振亦对股价形成提振。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"竞品申请撤回，翰森制药逆势上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670628758","title":"小摩：默沙东/第一三共撤回B7-H3 ADC申请 对翰森制药(03692)/GSK旗下Ris-Rez属正面","url":"https://stock-news.laohu8.com/highlight/detail?id=2670628758","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670628758?lang=zh_cn&edition=full","pubTime":"2026-09-28 15:56","pubTimestamp":1790582169,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根大通发布研报称，维持翰森制药“增持”评级，目标价50港元。默沙东与第一三共自愿撤回其B7-H3 ADC药物ifinatamab deruxtecan用于经治广泛期小细胞肺癌的美国生物制品许可申请，从竞争时序角度看，对翰森制药/GSK的Ris-Rez属增量正面。该行认为，Ris-Rez疗效数据看似领先I-DXd的II期结果，但试验设计及人群差异令两者不宜直接头对头比较。安全性方面，Ris-Rez治疗相关间质性肺病发生率为11.7%、无4/5级事件，I-DXd II期为12.4%，且包括>3级事件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0034235295.USD","IE00BJTD4N35.SGD","03692","BK1589","LU1914381329.SGD","XLF","KBWB","LU0048584097.USD","LU0106831901.USD","TRUF","LU0496365809.HKD","LU0203347892.USD","LU0971096721.USD","LU0208291251.USD","LU1496350171.SGD","BK4516","LU1363072403.SGD","LU1064131342.USD","LU1720051108.HKD","FTXO","LU2211815571.USD","IYG","VFH","JPMO","JPO","LU1894683264.USD","LU0417517546.SGD","FNCL","IE000MB6IJN5.SGD","LU1084165304.USD","LU0211326755.USD","LU1894683348.USD","TFNS","LU0265550359.USD","LU0265550946.USD","LU0323591593.USD","LU0234570918.USD","LU0215105999.USD","LU1366192091.USD","LU1670628061.USD","LU2357627491.SGD","IXG","LU0211326839.USD","IYF","LU1244550577.SGD","IE00BKVL7J92.USD","LU0689472784.USD","UYG","LU2237443895.HKD","LU2592432038.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670640324","title":"翰森制药(03692)：阿美替尼欧盟上市许可被撤销 拟重新递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2670640324","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670640324?lang=zh_cn&edition=full","pubTime":"2026-09-27 18:21","pubTimestamp":1790504485,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药 公布，有关阿美替尼单药治疗基于欧洲药品管理局人用药品委员会发表积极意见后于欧盟获批上市，欧盟委员会卫生和食品安全总司于2026年9月25日发布了一项实施决定，据此，上述上市许可被撤销。该集团已保留对该决定提出质疑的所有权利，包括在必要时透过欧盟法院诉讼程序提出质疑。集团亦拟尽快基于塬始数据资料包向EMA重新递交该产品的上市申请。目前，EMA已表示愿意缩短标准评估时间表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","FESXmain","03692","BK1191","BK1583","FSXEmain","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144276163","title":"翰森制药（03692）披露阿美替尼欧盟上市许可被撤最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1144276163","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144276163?lang=zh_cn&edition=full","pubTime":"2026-09-27 18:10","pubTimestamp":1790503833,"startTime":"0","endTime":"0","summary":"翰森制药集团有限公司9月27日发布自愿公告称，其抗肿瘤创新药阿美替尼的欧盟上市许可已被撤销。公告强调，该决定仅涉及监管程序问题，与药品的质量、安全性、有效性或临床价值无关。欧盟委员会卫生和食品安全总司于2026年9月25日作出实施决定，撤销阿美替尼的欧盟上市许可。翰森制药指出，公司将继续推进阿美替尼在其他司法管辖区的注册申请，并重申其“持续创新，提高人类生命质量”的战略目标。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670352419","title":"智通港股早知道 | 监管明确险资投资港股通ETF口径 海光芯正(01191)南向持股占比升至4.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670352419","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670352419?lang=zh_cn&edition=full","pubTime":"2026-09-25 07:52","pubTimestamp":1790293960,"startTime":"0","endTime":"0","summary":"预计本公司将于2026年12月31日前与相关方订立合伙协议及附属协议。 海光芯正：下半年1.6T光模块开始出货 南向持股占比升至4.2%海光芯正在9月9日至11日举行的第27届中国国际光电博览会上，展出全栈自研硅光1.6T光模块和6.4T NPO。此外，南向资金近期持续加仓，海光芯正已于今年9月7日起纳入港股通。截至目前，南向资金持有海光芯正384.44万股，占公司已发行普通股的4.19%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1537","IE0032431581.USD","IE00B5MMRT66.SGD","02628","LU1008478684.HKD","LU1226288170.HKD","LU1226287529.USD","FDN","LU1152091168.USD","LU2097828631.EUR","VXUS","LU1046422090.SGD","LU0173614495.USD","BK1230","BK1550","LU0287142896.SGD","03933","BK1521","LU0315179316.USD","00659","BK1589","01133","IE00B543WZ88.USD","01191","SG9999012710.SGD","LU0871576103.HKD","01093","LU1960683339.HKD","KCAI","LU0067412154.USD","BK1170","KURE","LU1226287792.SGD","LU0211977185.USD","LU1152091754.HKD","LU1226287875.USD","BK4550","IE00B3M56506.USD","BK1205","LU0307460666.USD","LU0320764599.SGD","LU0326950275.SGD","03692","LU1206782309.USD","FLHK","IE00B031HY20.USD","LU0140636845.USD","SG9999003461.SGD","LU2097828714.EUR","LU0708995583.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125416536","title":"翰森制药(03692)骨肉瘤创新ADC药物HS-20093上市申请获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1125416536","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125416536?lang=zh_cn&edition=full","pubTime":"2026-09-24 19:40","pubTimestamp":1790250042,"startTime":"0","endTime":"0","summary":"2026年9月24日，翰森制药集团有限公司（03692）发布自愿公告称，其自主研发的B7-H3靶向抗体-药物偶联物（ADC）“注射用瑞康立伏妥塔单抗（HS-20093）”的上市许可申请已获中国国家药品监督管理局（NMPA）受理。\n该产品拟用于治疗年龄≥12周岁且既往接受至少二线治疗失败的骨肉瘤患者。\n公告显示，HS-20093为翰森制药自主研发的创新药物，获得受理标志着其临床及注册进程迈出关键一步。\n公司董事会主席钟慧娟在公告中签署本次消息。至公告日，公司董事会由7名成员组成，包括3名执行董事和4名独立非执行董事。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669453987","title":"交银国际：上调翰森制药(03692)目标价至46港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2669453987","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669453987?lang=zh_cn&edition=full","pubTime":"2026-09-24 10:20","pubTimestamp":1790216436,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，上调翰森制药目标价至46港元，维持“买入”评级以及处方药行业重点推荐。该行指出，2027年有望上市Ris-Rez SCLC和骨肉瘤适应症、GLP-1/GIP、RET、c-MET等产品，Tyk2抑制剂和B7-H4 ADC有望于2028年获批。在WCLC大会上，III期ARTEMIS-008研究结果以最新突破性摘要形式公布。管理层维持2026年全年产品和合作收入均实现双位数增长的指引，主要来自创新药，其中阿美乐年销售额预计在2030年前超过80亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109089053","title":"异动解读｜翰森制药盘中下跌3.09%，报33.86港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1109089053","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109089053?lang=zh_cn&edition=full","pubTime":"2026-09-24 10:05","pubTimestamp":1790215553,"startTime":"0","endTime":"0","summary":"9月24日，翰森制药盘中下跌3.09%，报33.86港元，成交额4138.52万港元。翰森制药所在的制药行业整体承压，个股中，石药集团跌2.07%，中国生物制药跌2.55%，凯莱英跌4.2%，恒瑞医药跌2.63%，和黄医药涨0.27%。翰森制药集团有限公司是一家主要从事一系列药品的研发、生产及销售的投资控股公司，创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统疾病、代谢及其他治疗领域，主要在国内市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0762},{"period":"1month","weight":-0.0864},{"period":"3month","weight":-0.0045},{"period":"6month","weight":-0.1745},{"period":"1year","weight":-0.1357},{"period":"ytd","weight":-0.1131}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":-0.0421},{"period":"3month","weight":0.0015},{"period":"6month","weight":-0.065},{"period":"1year","weight":-0.095},{"period":"ytd","weight":-0.0554}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰森制药集团有限公司是一家主要从事一系列药品的研发、生产及销售的投资控股公司。该公司的创新药产品包括阿美乐、豪森昕福、迈灵达、孚来美、恒沐、昕越、圣罗莱等产品。该公司的创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统（CNS）疾病、代谢及其他治疗领域。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.002579},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.012814},{"month":3,"riseRate":0.428571,"avgChangeRate":0.023358},{"month":4,"riseRate":0.571429,"avgChangeRate":0.033967},{"month":5,"riseRate":0.571429,"avgChangeRate":-0.005202},{"month":6,"riseRate":0.571429,"avgChangeRate":0.039399},{"month":7,"riseRate":0.625,"avgChangeRate":0.011392},{"month":8,"riseRate":0.75,"avgChangeRate":0.028858},{"month":9,"riseRate":0.625,"avgChangeRate":-0.028026},{"month":10,"riseRate":0.125,"avgChangeRate":-0.011905},{"month":11,"riseRate":0.714286,"avgChangeRate":0.063438},{"month":12,"riseRate":0.571429,"avgChangeRate":0.016882}],"exchange":"SEHK","name":"翰森制药","nameEN":"HANSOH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰森制药,03692,翰森制药股票,翰森制药股票老虎,翰森制药股票老虎国际,翰森制药行情,翰森制药股票行情,翰森制药股价,翰森制药股市,翰森制药股票价格,翰森制药股票交易,翰森制药股票购买,翰森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}